Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2019

01-02-2019 | Hepatobiliary Tumors

National Failure of Surgical Staging for T1b Gallbladder Cancer

Authors: Elaine Vo, MD, Steven A. Curley, MD, Christy Y. Chai, MD, Nader N. Massarweh, MD, MPH, Hop S. Tran Cao, MD, FACS

Published in: Annals of Surgical Oncology | Issue 2/2019

Login to get access

Abstract

Background

Current guidelines recommend radical cholecystectomy with regional lymphadenectomy (RC-RL) for patients with T1b gallbladder cancer (GBC). However, the extent to which these guidelines are followed is unclear. This study aimed to evaluate current surgical practices for T1b GBC and their implications for overall management strategies and associated outcomes.

Methods

This retrospective cohort study investigated patients identified from the National Cancer Data Base (2004–2012) with non-metastatic T1b GBC. The patients were categorized according to type of surgical treatment received: simple cholecystectomy (SC) or RC-RL. Among the patients who had lymph nodes pathologically examined, nodal status was classified as pN− or pN+. Use of any adjuvant therapy was ascertained. Overall survival (OS) was compared based on type of surgical treatment and nodal status.

Results

The cohort comprised 464 patients (247 SC and 217 RC-RL cases). The positive margin status did not differ between the two groups (6.1% for SC vs 2.3% for RC-RL; p = 0.128). For RC-RL, the pN+ rate was 15%. Adjuvant therapies were used more frequently in pN+ (53.1% vs 9.4% for pN−). By comparison, 10.9% of the SC patients received adjuvant therapy. The OS for RC-RL-pN− (5-years OS, 64.4%) was significantly better than for RC-RL-pN+ (5-years OS, 15.7%) or SC (5-years OS, 48.3%) (p < 0.001).

Conclusion

Less than 50% of the patients with a T1b GBC primary tumor undergo the recommended surgical treatment. Given that 15% of these patients have nodal metastasis and in light of the previously described benefits of adjuvant therapy for node positive GBC, failure to perform RC-RL risks incomplete staging and thus undertreatment for patients with T1b GBC.
Literature
3.
5.
go back to reference Sun CD, Zhang BY, Wu LQ, Lee WJ. Laparoscopic cholecystectomy for treatment of unexpected early-stage gallbladder cancer. J Surg Oncol. 2005;91:253–7.CrossRefPubMed Sun CD, Zhang BY, Wu LQ, Lee WJ. Laparoscopic cholecystectomy for treatment of unexpected early-stage gallbladder cancer. J Surg Oncol. 2005;91:253–7.CrossRefPubMed
6.
go back to reference You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg. 2008;247:835–8.CrossRefPubMed You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg. 2008;247:835–8.CrossRefPubMed
7.
go back to reference Jensen EH, Abraham A, Habermann EB, Al-Refaie WB, Vickers SM, Virnig BA, Tuttle TM. A critical analysis of the surgical management of early-stage gallbladder cancer in the United States. J Gastrointest Surg. 2009;13:722–7.CrossRefPubMed Jensen EH, Abraham A, Habermann EB, Al-Refaie WB, Vickers SM, Virnig BA, Tuttle TM. A critical analysis of the surgical management of early-stage gallbladder cancer in the United States. J Gastrointest Surg. 2009;13:722–7.CrossRefPubMed
8.
go back to reference Tran Cao HS, Zhang Q, Sada YH, Chai C, Curley SA, Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer. 2018;124:74–83.CrossRefPubMed Tran Cao HS, Zhang Q, Sada YH, Chai C, Curley SA, Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer. 2018;124:74–83.CrossRefPubMed
9.
go back to reference Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy. Ann Surg. 2017;266:625–31.CrossRefPubMed Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy. Ann Surg. 2017;266:625–31.CrossRefPubMed
12.
go back to reference Benson AB III, Bekaii-Saab T, Ben-Josef E, et al. Hepatobiliary cancers: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006;4:728–50.CrossRef Benson AB III, Bekaii-Saab T, Ben-Josef E, et al. Hepatobiliary cancers: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006;4:728–50.CrossRef
13.
go back to reference Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11:1478–86; discussion 1486–7.PubMed Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11:1478–86; discussion 1486–7.PubMed
14.
go back to reference Jensen EH, Abraham A, Jarosek S, et al. Lymph node evaluation is associated with improved survival after surgery for early-stage gallbladder cancer. Surgery. 2009;146:706–11.CrossRefPubMed Jensen EH, Abraham A, Jarosek S, et al. Lymph node evaluation is associated with improved survival after surgery for early-stage gallbladder cancer. Surgery. 2009;146:706–11.CrossRefPubMed
15.
go back to reference Tran TB, Nissen NN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. J Gastrointest Oncol. 2015;6:452–8.PubMedPubMedCentral Tran TB, Nissen NN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. J Gastrointest Oncol. 2015;6:452–8.PubMedPubMedCentral
16.
go back to reference Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB Oxford. 2015;17:680–90.CrossRef Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB Oxford. 2015;17:680–90.CrossRef
18.
go back to reference Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;26:733–9.CrossRef Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;26:733–9.CrossRef
19.
go back to reference Lee W, Jeong CY, Jang JY, et al. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery. 2017;162:515–24.CrossRefPubMed Lee W, Jeong CY, Jang JY, et al. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery. 2017;162:515–24.CrossRefPubMed
20.
go back to reference Lee H, Choi DW, Park JY, et al. Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol. 2015;22:2779–86.CrossRefPubMed Lee H, Choi DW, Park JY, et al. Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol. 2015;22:2779–86.CrossRefPubMed
21.
go back to reference Abramson MA, Pandharipande P, Ruan D, Gold JS, Whang EE. Radical resection for T1b gallbladder cancer: a decision analysis. HPB Oxford. 2009;11:656–63.CrossRefPubMedPubMedCentral Abramson MA, Pandharipande P, Ruan D, Gold JS, Whang EE. Radical resection for T1b gallbladder cancer: a decision analysis. HPB Oxford. 2009;11:656–63.CrossRefPubMedPubMedCentral
Metadata
Title
National Failure of Surgical Staging for T1b Gallbladder Cancer
Authors
Elaine Vo, MD
Steven A. Curley, MD
Christy Y. Chai, MD
Nader N. Massarweh, MD, MPH
Hop S. Tran Cao, MD, FACS
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-7064-7

Other articles of this Issue 2/2019

Annals of Surgical Oncology 2/2019 Go to the issue